For the record - Oct. 8, 2007
- Share via
Breast cancer: An article in the Oct. 1 Health section stated that the medication raloxifene, or Evista, may soon be approved for breast cancer prevention in high-risk women. In fact, Evista was approved Sept. 14 for prevention of breast cancer in high-risk post-menopausal women and post-menopausal women with osteoporosis.
Sign up for Essential California
The most important California stories and recommendations in your inbox every morning.
You may occasionally receive promotional content from the Los Angeles Times.
